Tech Company Financing Transactions
Asgard Therapeutics Funding Round
Asgard Therapeutics, based in Lund, received $32.4 million from Johnson & Johnson Innovation, Boehringer Ingelheim Venture Fund and Industrifonden.
Transaction Overview
Company Name
Announced On
3/14/2024
Transaction Type
Venture Equity
Amount
$32,400,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support development of its lead program AT-108 to IND-readiness by 2026, expand and reinforce its research and development team, and accelerate new reprogramming modalities and delivery platforms to strengthen the pipeline.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Medicon Village
Lund, 223 81
Sweden
Lund, 223 81
Sweden
Phone
Website
Email Address
Overview
Asgard Therapeutic's mission is to pioneer direct cell reprogramming for cancer immunotherapy. Our current focus is to develop scalable reprogramming technologies enabling the direct in vivo conversion of cancer cells into professional antigen-presenting dendritic cells, reinstating cancer immunity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cristiana Pires
Chief Financial Officer
Jan Villadsen
Chief Technical Officer
Filipe Pereira
VP - R & D
Fábio Rosa
Browse more venture capital transactions:
Prev: 3/14/2024: Pi Health venture capital transaction
Next: 3/14/2024: Unstructured venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs